中晚期原发性肝癌的TACE治疗和FOLFOX4方案化疗疗效分析  

Contrastive study of TACE and FOLFOX4 in chemotherapeutic treatment of advanced primary hepatic carcinoma

作　　者：丁德权[1] 曹齐生[1] 何昌霞[1] 陈磊[1] 

机构地区：[1]安徽省马鞍山市人民医院肿瘤介入科,安徽马鞍山243000

出　　处：《安徽医药》2013年第8期1388-1391,共4页Anhui Medical and Pharmaceutical Journal

摘　　要：目的探讨含奥沙利铂为主的方案行肝动脉化疗栓塞术(TACE)和FOLFOX4方案(L-OHP+CF/5-Fu)静脉化疗治疗原发性肝癌有效性与安全性。方法 2008年7月—2012年3月,76例PHC患者,51例患者接受含奥沙利铂为主的方案TACE治疗,25例患者接受FOLFOX4方案(L-OHP+CF/5-Fu)静脉化疗,记录两组病例肿瘤病灶长径总和、AFP变化、肿瘤进展时间(TTP),计算两组病例治疗有效率(RR)和生存率,并对比分析两组病例生存影响因素。结果随访18个月(1～24个月),含奥沙利铂为主的方案TACE治疗组患者1年生存率66.67%,肿瘤进展时间为2.5～14.5个月,中位TTP为7.8个月;FOLFOX4方案静脉化疗组患者1年生存率52.38%,肿瘤进展时间(TTP)为1.5～13.5个月,中位TTP为4.7个月;奥沙利铂为主的方案TACE治疗组患者AFP下降比例和TTP明显优于FOLFOX4方案静脉化疗组;两组患者治疗毒副反应的发生均为临床常见的毒副反应,可给予对症治疗纠正和改善。结论含奥沙利铂为主方案的TACE治疗和FOLFOX4方案(L-OHP+CF/5-Fu)静脉化疗均为治疗原发性肝癌有效的治疗方法,但含奥沙利铂为主方案的TACE治疗疗效明显优于FOLFOX4方案静脉化疗。Objective To investigate the efficacy and safety of transcatheter arterial chemoembolization（TACE） with oxaliplatin and intravenous chemotherapy with FOLFOX4（L-OHP ＋ CF /5-Fu）.Methods During the period from July 2008 to March 2012,76 primary hepatic carcinoma（PHC） patients were randomized into two groups： 51 patients were given TACE treatment with oxaliplatin and 25 patients were given intravenous chemotherapy with FOLFOX4（L-OHP ＋ CF /5-Fu）.The change of the sum diameter of target lesions,alpha fetal protein（AFP） and time of tumor progression（TTP） were recorded so that the response rate（RR） and survival rate of two groups could be calculated and the factors that influenced the survival of patients from both groups could be contrastively analyzed.Results The treatment efficacy was comprehensively investigated during averaged 18 months（1 ～ 24 months） of follow-up observation.In the TACE with oxaliplatin group,one-year survival rate was 66.7%;the TTP was 2.5 ～ 14.5 months;the median TTP was 7.8 months.In contrast,in the FOLFOX4 intravenous chemotherapy group,one-year survival rate was 52.38%;the TTP was 1.5 ～ 13.5 months,the median TTP was 4.7 months.In addition,insofar as the change of AFP,TTP and one-year survival rate was concerned,the TACE with oxaliplatin group was significantly preferable to the FOLFOX4 group.The toxic and side effects in both groups were common in clinical practice and could be relieved or improved through symptomatic treatment.Conclusion Both TACE with oxaliplatin and intravenous chemotherapy with FOLFOX4（L-OHP ＋ CF /5-Fu） are effective methods in treating primary hepatic carcinoma,however,the treatment effect of TACE with oxaliplatin is significantly better than that of intravenous thermotherapy with FOLFOX4.

关 键 词：原发性肝癌 肝动脉化疗栓塞术 奥沙利铂 FOLFOX4方案 

分 类 号：R735.7[医药卫生—肿瘤]